NYSE: AORT · Medical Devices
Artivion (AORT) fair value and price range
As of 26 Sep 2026, Faircurve's model values Artivion (AORT) at $21.44 a share. The stock last closed at $22.31, which puts the model's fair value 3.9% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Artivion, Inc.
Faircurve Insights · 26 Sep 2026
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues.
Faircurve's model found a fair value of $21.44 a share on 26 Sep 2026, the midpoint of 2,000 simulations. The previous run on 19 Sep 2026 gave $21.97, and the fair value moved -2.4%. The calibrated range over 63 trading days is $17.99 to $26.14, built from the fair value since there is no live options data for the stock; ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
The overall quality score is 50 out of 100, against comparable companies. The model compares it with Tandem Diabetes Care, Inc., Enovis Corporation, CONMED Corporation, Cytek Biosciences, Inc., and UFP Technologies, Inc. The stock's moves around its last 8 earnings reports ranged from +26.9% to -26.8%, with a median size, ignoring direction, of 9.1%.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give AORT?
The calibrated range for AORT over 63 trading days is $17.99 to $26.14. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $11.45 to $36.00. In 47% of the simulations the fair value came out above the price the model ran on.
How does AORT score on business quality?
Artivion's overall quality score is 50 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 34 | 1.6%ROIC | 2.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 62 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 73 | 13.6%Revenue growth, trailing | 7.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 37 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 4 | 5.76xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 88 | 1.8 ptsEBITDA margin downside volatility, 5y | 6.3 pts |
How does AORT compare with similar companies?
The companies in medical devices closest to Artivion in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| TNDM Tandem Diabetes Care, Inc. | $16.50 | $23.82 | +44.4% | Undervalued |
| ENOV Enovis Corporation | $17.77 | $25.00 | +40.7% | Undervalued |
| IART Integra LifeSciences Holdings Corporation | $12.68 | $18.08 | +42.6% | Low evidence grade |
| CNMD CONMED Corporation | $46.32 | $56.50 | +22.0% | Undervalued |
| AHCO AdaptHealth Corp. | $5.60 | $5.63 | +0.5% | Low evidence grade |
| CTKB Cytek Biosciences, Inc. | $5.87 | $6.47 | +10.2% | Fairly valued |
| INSP Inspire Medical Systems, Inc. | $69.97 | $70.21 | +0.3% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $300.70 | $275.24 | -8.5% | Fairly valued |
When does AORT report earnings, and how has the stock reacted?
Artivion's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
How AORT moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 9.1%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | +3.6% |
| 7 May 2026 | -26.8% |
| 12 Feb 2026 | -8.7% |
| 6 Nov 2025 | -3.5% |
| 7 Aug 2025 | +26.9% |
| 5 May 2025 | +24.0% |
| 24 Feb 2025 | -9.6% |
| 7 Nov 2024 | -2.5% |
Artivion at a glance
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues.
- Market value
- $1.1B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $530M
- Consensus revenue growth, next fiscal year
- +11.1%
- Analysts with estimates
- 4
- Beta to the US market
- 0.09
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Artivion on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for AORT was $21.97. As of 26 Sep 2026 it is $21.44, a change of -2.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Artivion's valuation
Is Artivion stock undervalued or overvalued?
Faircurve's model puts AORT's fair value at $21.44 a share against a last close of $22.31, as of 26 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is AORT's fair value?
$21.44 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $11.45 to $36.00.
What price range does the model give AORT?
$17.99 to $26.14 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Artivion report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has AORT moved on past earnings reports?
Across its last 8 reports the median two session move was 9.1%, ignoring direction. The largest was +26.9% around the report of 7 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for AORT is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.